Cost-effectiveness of pemigatinib as a second-line treatment for advanced intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 fusions in Taiwan: from the evidence of the phase II trial and the perspective of Taiwan's National Health Insurance Administration
Saved in:
| Title: | Cost-effectiveness of pemigatinib as a second-line treatment for advanced intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 fusions in Taiwan: from the evidence of the phase II trial and the perspective of Taiwan's National Health Insurance Administration |
|---|---|
| Authors: | Chen, Zi-Rong1 (AUTHOR), Chueh, Chen-Han1 (AUTHOR), Chiang, Nai-Jung2,3 (AUTHOR) njchiang@vghtpe.gov.tw, Tsai, Yi-Wen1 (AUTHOR) ywtsai@nycu.edu.tw |
| Source: | Cost Effectiveness & Resource Allocation. 9/11/2023, Vol. 21 Issue 1, p1-10. 10p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 14787547 |
|---|---|
| DOI: | 10.1186/s12962-023-00473-5 |
